Wall Street analysts will be watching closely when ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) reports its quarterly earnings next, which is scheduled for Tue 26 Feb (In 51 Days). Looking at the latest analyst forecasts, the current earnings-per-share (EPS) consensus estimate is sitting at -$0.46 per share. In the preceding quarter, the company reportedly generated EPS of -$0.50 per share of its common stock. Looking at profitability indicators, this organization has an operating margin of , a profit margin of and a gross margin of 94.20%.
Speaking of Wall Street analysts, a number of market experts at top investment banks have recently posted their updated ratings on shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Most recently, on December 10th, 2018, Canaccord Genuity Initiated a Hold rating. Before that, on September 21st, 2018, Piper Jaffray Upgrade to Overweight. Stifel Reiterated a Hold rating on August 9th, 2018, Stifel Initiated an Hold rating on August 7th, 2018, and Piper Jaffray Downgrade a Neutral rating on August 6th, 2018.
At its current price point, combined with the fact that this company has 133.81M shares outstanding, the current market capitalization sits at 2.35B. In the last trading day, 2,198,425 shares of ACADIA Pharmaceuticals Inc. were traded, which compares to its usual volume of about 2.53M shares per day of trading.
If we compare this company’s current price to its recent pricing activity, we can see that the price has changed by $2.12 in the past five trading days, resulting in a percentage change of +12.27% and a moving average of 16.44. In the past 20 days, its price changed by -$1.25 (which is -6.64%) and the stock’s moving average was 16.82. Looking back a full 50 days, shares of ACAD changed by -$4.19 (which is -19.26%) and demonstrated a moving average of 18.59.
Staying in the same analytical area, this company’s stock has demonstrated a 9-day Stochastic %K score of 78.66%, a 14-day Stochastic %K score of 57.54% and a 20-day Stochastic %K score of 45.33%. Using a similar metric, ACADIA Pharmaceuticals Inc. (ACAD) shares showed a Stochastic %D of 67.84% over the past 9 days, a Stochastic %D score of 48.29% over the last 14 days, and a 20-day Stochastic %D of 37.92%. Meanwhile, this stock’s MACD Oscillator was 1.00 over the past 9 days, 0.69 over the past two weeks, and -0.02 in the last 20 days.
As recent trading data suggests, this company’s shares have been hovering close to the $17.57 level. Over the past 12 months, this stock has experienced a high price of $32.99 and a low of $12.77. Top market experts pay heightened attention to a stock as it is getting closer to a notable historic high price or low price.
Baker Bros Advisors LP purchased more shares of this company during the last fiscal quarter, as we can observe in the latest corresponding filing from ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with the Securities and Exchange Commission (SEC). This specific major shareholder, at the end of the quarter, held 39,713,842 shares of the company’s stock following the addition of 11,274,728 to this investor’s holdings during the three-month period. This share count represents that Baker Bros Advisors LP now held 27.65% stake in ACADIA Pharmaceuticals Inc. (ACAD)’s shares.
Just in the most recent trading day, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) experienced a high price of $17.65 and low point of $16.44. At the end of the last trading session, this stock was at 17.57 per share, following a gain of $0.27, or 8.66% during the full day.